UNSPSC 51343805: Interferon alfa-2b/ribavirin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

UNSPSC 51343805 Interferon alfa-2b/ribavirin is a Commodity code that shows little relevant recent activity aligned with its nominal scope. The two most recent state and local contract opportunities tagged to this code involve pharmaceutical procurement but do not include interferon alfa-2b/ribavirin: the Illinois Department of Public Health awarded a piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride supply ($2.999999 million over three years), and Seminole County, Florida issued an IFB on June 30, 2026 for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford.

The mismatch between the code's specified antiviral therapy and the actual pharmaceutical products being procured suggests either classification error at the point of tagging or that this code does not currently capture active state and local demand for interferon alfa-2b/ribavirin. No open solicitations, active pre-bid activity, or representative opportunities for the specified commodity appear in the recent record. Firms evaluating pursuit under this code should verify that their target customers are actively soliciting this specific antiviral combination therapy through state and local channels before committing bid resources.